X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline
Authors:
- Dalal S AliDADalal S Ali
- Thomas O CarpenterTCThomas O Carpenter
- Erik A ImelEIErik A Imel
- Leanne M WardLWLeanne M Ward
- Natasha M Appelman-DijkstraNANatasha M Appelman-Dijkstra
- Catherine ChaussainCCCatherine Chaussain
- Suzanne M Jan de BeurSBSuzanne M Jan de Beur
- Pablo FlorenzanoPFPablo Florenzano
- Hajar Abu AlrobHAHajar Abu Alrob
- R Todd AlexanderRAR Todd Alexander
- Farah AlsarrafFAFarah Alsarraf
Top Cited Papers
Open Access
- 17 February 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (7) , 2055-2070
Abstract
Context: An International Working Group (IWG) developed new guidelines on the diagnosis, evaluation, management, and monitoring of X-linked hypophosphatemia (XLH) in children. Over the past 5 years, important advances have occurred in our understanding of the presentation, complications, and treatment of XLH. Methods: A group of 50 international experts in XLH from Canada, the United States, Europe, Asia, and South America, along with methodology experts and a patient partner, held 18 teleconference meetings in 2023-2024. These meetings addressed key issues regarding diagnosing, evaluating, managing, and monitoring XLH in children. Two systematic reviews were conducted to examine the impact of burosumab compared to conventional therapy (phosphate salts and active vitamin D) or no therapy, and to assess the impact of conventional therapy vs no therapy on patient-important outcomes. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Additionally, narrative reviews were completed on XLH diagnosis and the role of genetic testing, and an expert clinical practice survey informed the monitoring recommendations. Outcomes: An approach to establishing the diagnosis of XLH is presented. GRADEd recommendations were developed on treatment strategies for XLH in children. Monitoring recommendations, GRADEd as weak with very low certainty, were based on clinical practice survey of the IWG experts. The guidelines also addressed dental complications and proposed potential strategies to mitigate them. Conclusion: These clinical practice guidelines provide an update of the current evidence on the diagnosis and management of XLH and provide a comprehensive guidance for multidisciplinary healthcare professionals involved in the care of children with XLH.Keywords
Funding Information
- Calcium disorders clinic
- McMaster University
This publication has 121 references indexed in Scilit:
- Asia‐Pacific Consensus Recommendations on X‐Linked Hypophosphatemia: Diagnosis, Multidisciplinary Management, and Transition From Pediatric to Adult CareJBMR Plus, 2023
- Craniosynostosis in Patients With X‐Linked Hypophosphatemia: A ReviewJBMR Plus, 2023
- Burosumab and Dental Abscesses in Children With X‐Linked HypophosphatemiaJBMR Plus, 2022
- Lower limb bone geometry in adult individuals with X-linked hypophosphatemia: an observational studyOsteoporosis International, 2022
- Mineralization Defects in the Primary Dentition Associated With X‐Linked Hypophosphatemic RicketsJBMR Plus, 2021
- Hyperparathyroidism in Patients With X-Linked HypophosphatemiaJournal of Bone and Mineral Research, 2020
- Management of bone disease in cystinosis: Statement from an international conferenceJournal of Inherited Metabolic Disease, 2019
- High Incidence of Cranial Synostosis and Chiari I Malformation in Children With X-Linked Hypophosphatemic Rickets (XLHR)Journal of Bone and Mineral Research, 2018
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary AnalysisJournal of Bone and Mineral Research, 2018
- A clinician's guide to X-linked hypophosphatemiaJournal of Bone and Mineral Research, 2011